Floatz logo

Apixaban

Anticoagulants

PfizerSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Anticoagulants cohort.

Asset / SponsorPhaseRating
BIVALIRUDIN
University of Texas Southwestern Medical Center
Phase 4BB
Enoxaparin
University of Utah
Phase 4BB
Acetylsalicylic Acid
University Hospital, Bordeaux
Phase 4BB
Plavix
University Hospital, Bordeaux
Phase 4BB
Unfractionated Heparin
University of Texas Southwestern Medical Center
Phase 4B

Same molecule, other indications

Apixaban is also rated in:

venous thromboembolismDormant
BBB
Indicative ·
79 / 100
View asset →
venous thromboembolismDormant
BBB
Indicative ·
79 / 100
View asset →
atrial fibrillationDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →